Clinical Trial Update: Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

View source ↗

Summary

Marketing approval granted for maraviroc (MK0518) in combination with optimized background antiretroviral therapy for HIV infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Selzentry (Maraviroc)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Infections | Status: APPROVED_FOR_MARKETING